Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J
Gynecologic Cancer Program, Cleveland Clinic Taussig Cancer Center, OH 44195, USA.
Gynecol Oncol. 2000 Jul;78(1):43-6. doi: 10.1006/gyno.2000.5824.
The purpose of this study was to develop a cost-effective prophylactic antiemetic regimen for the prevention of carboplatin-induced emesis.
Patients being treated in the Gynecologic Cancer Program of the Cleveland Clinic Taussig Cancer Center with a carboplatin-based chemotherapy regimen received a prophylactic antiemetic program consisting of a single dose of oral ondansetron (16 mg) plus intravenous dexamethasone (20 mg) approximately 30 min prior to chemotherapy. Evaluation of the effectiveness of this antiemetic regimen was performed during a single treatment course.
A total of 27 patients (median age, 62; range, 41-83) participated in this phase 2 trial. Three patients received single-agent carboplatin, and 24 were treated with either a carboplatin/paclitaxel or carboplatin/docetaxel regimen. The carboplatin AUC dosing level was 4, 5, or 6 in 6, 5, and 16 individuals, respectively. No patient developed vomiting; 2 (7%) individuals experienced nausea during the 24-h period following chemotherapy administration.
The combination of a single dose of oral ondansetron (16 mg) plus intravenous dexamethasone (20 mg) is an effective prophylactic antiemetic regimen for patients receiving carboplatin-based chemotherapy.
本研究旨在制定一种具有成本效益的预防性止吐方案，用于预防卡铂所致呕吐。
在克利夫兰诊所陶西格癌症中心妇科癌症项目中接受以卡铂为基础的化疗方案治疗的患者，在化疗前约30分钟接受由单剂量口服昂丹司琼（16毫克）加静脉注射地塞米松（20毫克）组成的预防性止吐方案。在单个治疗疗程中对该止吐方案的有效性进行评估。
共有27例患者（中位年龄62岁；范围41 - 83岁）参与了这项2期试验。3例患者接受单药卡铂治疗，24例接受卡铂/紫杉醇或卡铂/多西他赛方案治疗。卡铂AUC给药水平分别为4、5或6的患者有6例、5例和16例。无患者发生呕吐；2例（7%）患者在化疗给药后的24小时内出现恶心。
单剂量口服昂丹司琼（16毫克）加静脉注射地塞米松（20毫克）的联合方案，对于接受以卡铂为基础化疗的患者是一种有效的预防性止吐方案。
